$INO INOVIO Announces Positive Interim Phase 1 Data For INO-4800 Vaccine for COVID-19

94% (34 out of 36 total trial participants) demonstrated overall immunological response rates 

$MRNA $NVAX $SRNE $CODX $VRTX $JNJ $PFE $MRK $AZN $GILD #COVID19  https://t.co/GfqoAYz8Ia